Solid Biosciences Inc. Operating Income

Quick Answer

Solid Biosciences Inc. reported Operating Income of -$179.21 million for fiscal year 2025.

Solid Biosciences Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$179.21M -38.1%
2024 -$129.73M -24.4%
2023 -$104.25M +2.1%
2022 -$106.45M -47.3%
2021 -$72.25M +18.3%
2020 -$88.41M +25.9%
2019 -$119.32M -57.6%
2018 -$75.69M -38.0%
2017 -$54.86M -114.5%
2016 -$25.58M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$48.06M -36.6% -15.3%
June 30, 2025 -$41.69M -50.0% -4.1%
March 31, 2025 -$40.05M -49.1% -13.8%
September 30, 2024 -$35.18M -52.2% -26.6%
June 30, 2024 -$27.79M -3.5% -3.4%
March 31, 2024 -$26.86M +16.1% -16.2%
September 30, 2023 -$23.11M -9.4% +13.9%
June 30, 2023 -$26.84M -5.8% +16.2%
  • Solid Biosciences Inc. showed a decrease of -38.1% in Operating Income compared to the prior fiscal year.
  • Over the 2016–2025 period, Solid Biosciences Inc.’s operating income has declined by 600.7% (from -$25.58 million to -$179.21 million).
  • The most recent figure is from Solid Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment